@article{JTD26082,
author = {Concetta Elisa Onesti and Pierre Frères and Guy Jerusalem},
title = {Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {1},
year = {2018},
keywords = {},
abstract = {Over the last 5 years, immunotherapy has become one of the backbones for cancer treatment, showing significant improvement in prognosis for several malignancies. Currently, in clinical practice, we have several immune checkpoint inhibitors targeting cytotoxic T lymphocyte associated antigen 4 (CTLA4), programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1), while several other drugs, directed toward different co-inhibitory or co-stimulatory molecules, are under evaluation (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/26082}
}